Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

  1. Provencio, M.
  2. Terrasa, J.
  3. Garrido, P.
  4. Campelo, R.G.
  5. Aparisi, F.
  6. Diz, P.
  7. Aguiar, D.
  8. García-Giron, C.
  9. Hidalgo, J.
  10. Aguado, C.
  11. González, J.G.
  12. Esteban, E.
  13. Gómez-Aldavarí, L.
  14. Moran, T.
  15. Juan, O.
  16. Chara, L.E.
  17. Marti, J.L.
  18. Castro, R.L.
  19. Ortega, A.L.
  20. Moreno, E.M.
  21. Coves, J.
  22. Sánchez Peña, A.M.
  23. Bosch-Barrera, J.
  24. Gastaldo, A.S.
  25. Núñez, N.F.
  26. del Barco, E.
  27. Cobo, M.
  28. Isla, D.
  29. Majem, M.
  30. Navarro, F.
  31. Calvo, V.
  32. Show all authors +
Journal:
BMC Cancer

ISSN: 1471-2407

Year of publication: 2021

Volume: 21

Issue: 1

Type: Article

DOI: 10.1186/S12885-021-07922-5 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus